<DOC>
	<DOC>NCT02960854</DOC>
	<brief_summary>A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.</brief_summary>
	<brief_title>A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock, Septic</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Men and women ages â‰¥ 18 years old Documented or suspected infection Severe sepsis or septic shock for at least 24 hours Sepsisinduced immunosuppression In Intensive Care Unit (ICU) with no plans to discharge in next 24 hours Previous episode of severe sepsis or septic shock with ICU admission during the current hospitalization Autoimmune disease Organ or bone marrow transplant Cancer treatment in the past 6 weeks Human immunodeficiency virus (HIV) infection and not on therapy prior to this episode of sepsis; hepatitis C virus(HCV) infection and still has virus (not cured); Chronic hepatitis B virus (HBV) infection and not on treatment Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>